BMS-986365
Sponsors
Celgene Corp., UroTrials GmbH, AIO-Studien gGmbH, Celgene
Conditions
Healthy ParticipantsHealthy VolunteersMetastatic Castrate Sensitive Prostate Cancer - mCSPCMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
CompletedNCT06417229
Start: 2024-05-28End: 2025-02-19Updated: 2025-03-06
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
CompletedNCT06433505
Start: 2024-05-30End: 2025-02-28Updated: 2025-03-26
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
TerminatedNCT07242781
Start: 2025-12-15End: 2026-04-21Updated: 2026-07-20
Phase 2
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Active, not recruitingNCT06764485
Start: 2025-03-13End: 2029-01-19Target: 960Updated: 2026-09-08
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
RecruitingCTIS2024-517422-25-00
Start: 2025-05-22Target: 374Updated: 2026-01-14